ArticleAmerican journal of cancer research2025
Long noncoding RNA VPS9D1-AS1 promotes angiogenesis in colorectal cancer by regulating the VEGFA signalling pathway.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VPS9D1-AS1: a critical oncogenic long non-coding RNA in human malignancies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To clarify the mechanism of long non-coding RNA VPS9D1-AS1 affecting angiogenesis in colorectal cancer (CRC). Western blot and qRT-PCR assays were performed to detect the expression of VPS9D1-AS1 in colorectal cancer. The effects of VPS9D1-AS1 regulating VEGFA and affecting the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVECs) were examined using cell biology, in vitro tubeformation and Chorioallantoic membrane vascular assay. Chromatin Immunoprecipitation (ChIP) and dual luciferase assays were performed to verify the specific sites of transcription factor binding to the promoter region of VPS9D1-AS1. VPS9D1-AS1 is highly expressed in colorectal cancer. Interfering with VPS9D1-AS1 inhibited the proliferation, invasion and migration of HUVECs. Mechanistically, VPS9D1-AS1 can promote angiogenesis by upregulating VEGFA expression and activating the downstream PI3K/AKT pathway. In addition, CEBPB is a transcription factor of VPS9D1-AS1 predicted by database, and the results of ChIP experiments showed that CEBPB could directly bind to the VPS9D1-AS1 promoter region at the -698 bp to -794 bp site. The results of dual luciferase assay showed that CEBPB could enhance VPS9D1-AS1 promoter activity and promote its transcription. VPS9D1-AS1 can be activated by CEBPB transcription factor and target VEGFA to activate its downstream pathway to promote colorectal cancer angiogenesis, which may suggest that VPS9D1-AS1 is critical for regulating colorectal cancer angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.